Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France.
Programme Cartes d'Identité des Tumeurs, Ligue Nationale contre le Cancer, Paris, France.
J Exp Med. 2021 Jan 4;218(1). doi: 10.1084/jem.20200851.
Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.
虽然 T 细胞被认为是肿瘤微环境中的主要免疫细胞，能够诱导肿瘤消退并控制癌症的临床结果，但最近大量的出版物指出，B 细胞也可能发挥突出作用。在三级淋巴结构的生发中心中激活的 B 细胞可以直接将肿瘤相关抗原呈递给 T 细胞，或者产生增加抗原呈递给 T 细胞或杀死肿瘤细胞的抗体，从而产生有益的临床影响。免疫复合物还可以通过巨噬细胞和补体的激活增加炎症、血管生成和免疫抑制，从而产生有害影响。
